Met s

 Here are 3 points summarizing the systemic impacts of Metabolic dysfunction-associated steatotic liver disease and Metabolic dysfunction-associated steatohepatitis, as discussed by Reddemma Sandireddy:

1. Heart (cardiovascular disease risk increases)
   MASLD/MASH promote systemic inflammation, insulin resistance, and atherogenic lipid profiles. These changes accelerate atherosclerosis, leading to higher risk of coronary artery disease, heart failure, and cardiovascular mortality—often the leading cause of death in MASLD patients.
2. Muscle (sarcopenia and insulin resistance)
   Metabolic dysfunction in MASLD/MASH is linked to skeletal muscle loss (sarcopenia) and reduced muscle glucose uptake. Muscle insulin resistance worsens hyperglycemia, creating a cycle where muscle weakness and metabolic disease reinforce each other.
3. Kidney (chronic kidney disease progression)
   Systemic inflammation, oxidative stress, and altered lipid metabolism in MASLD/MASH contribute to chronic kidney disease (CKD). Patients show increased albuminuria, reduced glomerular filtration rate, and higher risk of diabetic and hypertensive nephropathy.

In short:

• Heart → atherosclerosis & cardiovascular mortality
• Muscle → sarcopenia & insulin resistance
• Kidney → CKD & renal function decline